Studie über die Interaktionen (Wechselwirkungen) zwischen Rivaroxaban und Johanniskraut

Drug: St Johns Wort Extract;Drug: Rivaroxaban

Inclusion Criteria:

- Men or women, age between 18 and 45 years (inclusive) at screening

- BMI between 18 and 28 kg/m2 (inclusive) at screening

- No clinically significant findings on the physical examination at screening

- Hematology and clinical chemistry results not deviating from the normal range to a
clinically relevant extent at screening

- Ability to communicate well with the investigator and to understand and comply with
the requirements of the study

- Women of child-bearing age: willingness of using a double barrier contraception method
during the study, i.e. a hormonal method (oral contraceptive, intrauterine device) in
combination with a mechanical barrier (e.g. condom, diaphragm)

- Signed informed consent

Exclusion Criteria:

- Known allergic reaction to any excipient of the drug formulations

- Known photosensitivity

- Smoking

- History or clinical evidence of alcoholism or drug abuse within the 3-year period
prior to screening

- Loss of = 250 ml of blood within 3 months prior to screening, including blood donation

- Treatment with an investigational drug within 30 days prior to screening

- Previous treatment with any prescribed or over-the-counter medications (including
herbal medicines such as St. John's wort) within 2 weeks prior to screening

- Pregnant (positive results from urine drug screen at screening) or lactating women

- History or clinical evidence of any disease (e.g. gastrointestinal tract disease)
and/or existence of any surgical or medical condition, which might interfere with the
absorption, distribution, metabolism or excretion of the study drugs, or which might
increase the risk for toxicity

- Legal incapacity or limited legal capacity at screening

- Any circumstances or conditions, which, in the opinion of the investigator, may affect
full participation in the study or compliance with the protocol